In
the UK & Ireland, Procter & Gamble Pharmaceuticals (P&GP)
are specialists in the treatment
of post-menopausal osteoporosis, a disease that weakens bones,
making them more likely to fracture.
Generally, the main focus areas for P&GP are bone/musculoskeletal, cardiac, anti-infectives, and gastro-intestinal.
P&GP has a strong marketing and
selling capability in the UK and Ireland,
particularly with specialists such
as rheumatologists, geriatricians
and endocrinologists.
PRODUCTS
- Didronel 200mg tablets
-
Didronel PMO tablets
-
Dantrium 25mg capsules
-
Dantrium 100mg capsules
-
Dantrium Intravenous
-
Actonel 5mg tablets
-
Actonel 30mg tablets
-
Actonel 35mg tablets
-
Asacol 250mg suppositories
-
Asacol 400mg tablets
-
Asacol 500mg suppositories
-
Asacol Foam Enema
-
Cacit 500mg tablets
-
Cacit D3 440 IU sachets
-
Regulan Orange sachets
-
Regulan Lemon/Lime sachets
HISTORY
P&G entered the Pharmaceutical business
in 1982 with the purchase of
the US company, Norwich Eaton.
Procter & Gamble
pioneered knowledge in the field
of bone metabolism and furthered
the role of bisphosphonates for
use in osteoprosis, stemming
from early research with laundry
detergent technology.
Although
owned and operated by P&G,
the company continued to trade as Norwich
Eaton until 1992, when the name was
changed to Procter & Gamble Pharmaceuticals
(P&GP). P&GP is growing rapidly,
with operations in the U.S., Canada,
and Western Europe
If
you wish to find out more about P&G
Pharmaceuticals, please visit
our websites : |
